Search research articles
Contact Us
Filters
Showing results (81-90 of 226) with videos related to
Page
of 23
Sort By:
Critical Care Medicine
|
March 11, 2003
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial
Jean-Louis Vincent, Derek C Angus, Antonio Artigas, et al.
JAMA
|
October 4, 2017
Effect of an Early Resuscitation Protocol on In-hospital Mortality Among Adults With Sepsis and Hypotension: A Randomized Clinical Trial
Ben Andrews, Matthew W Semler, Levy Muchemwa, et al.
Critical Care Medicine
|
July 1, 2006
Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis
Todd W Rice, Arthur P Wheeler, Peter E Morris, et al.
Critical Care Medicine
|
January 23, 2008
A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome
Peter E Morris, Peter Papadakos, James A Russell, et al.
Annals of Intensive Care
|
September 25, 2013
Longer storage duration of red blood cells is associated with an increased risk of acute lung injury in patients with sepsis
David R Janz, Zhiguo Zhao, Tatsuki Koyama, et al.
Critical Care Medicine
|
July 9, 2015
Atrial Fibrillation Is an Independent Predictor of Mortality in Critically Ill Patients
Ciara M Shaver, Wei Chen, David R Janz, et al.
BMC Pulmonary Medicine
|
February 5, 2017
Early exposure to hyperoxia and mortality in critically ill patients with severe traumatic injuries
Derek W Russell, David R Janz, William L Emerson, et al.
Academic Medicine : Journal of the Association of American Medical Colleges
|
June 23, 2012
Clinical and translational research studios: a multidisciplinary internal support program
Daniel W Byrne, Italo Biaggioni, Gordon R Bernard, et al.
Chest
|
June 11, 2004
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis
Gordon R Bernard, Benjamin D Margolis, Harvey M Shanies, et al.
Critical Care Medicine
|
January 11, 2005
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis
Derek C Angus, Pierre-Francois Laterre, Jeff Helterbrand, et al.
Page
of 23
Search research articles
Search
Showing results (81-90 of 226) with videos related to
Sort By:
Page
of 23
Critical Care Medicine
|
March 11, 2003
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial
Jean-Louis Vincent, Derek C Angus, Antonio Artigas, et al.
JAMA
|
October 4, 2017
Effect of an Early Resuscitation Protocol on In-hospital Mortality Among Adults With Sepsis and Hypotension: A Randomized Clinical Trial
Ben Andrews, Matthew W Semler, Levy Muchemwa, et al.
Critical Care Medicine
|
July 1, 2006
Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis
Todd W Rice, Arthur P Wheeler, Peter E Morris, et al.
Critical Care Medicine
|
January 23, 2008
A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome
Peter E Morris, Peter Papadakos, James A Russell, et al.
Annals of Intensive Care
|
September 25, 2013
Longer storage duration of red blood cells is associated with an increased risk of acute lung injury in patients with sepsis
David R Janz, Zhiguo Zhao, Tatsuki Koyama, et al.
Critical Care Medicine
|
July 9, 2015
Atrial Fibrillation Is an Independent Predictor of Mortality in Critically Ill Patients
Ciara M Shaver, Wei Chen, David R Janz, et al.
BMC Pulmonary Medicine
|
February 5, 2017
Early exposure to hyperoxia and mortality in critically ill patients with severe traumatic injuries
Derek W Russell, David R Janz, William L Emerson, et al.
Academic Medicine : Journal of the Association of American Medical Colleges
|
June 23, 2012
Clinical and translational research studios: a multidisciplinary internal support program
Daniel W Byrne, Italo Biaggioni, Gordon R Bernard, et al.
Chest
|
June 11, 2004
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis
Gordon R Bernard, Benjamin D Margolis, Harvey M Shanies, et al.
Critical Care Medicine
|
January 11, 2005
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis
Derek C Angus, Pierre-Francois Laterre, Jeff Helterbrand, et al.
Page
of 23